If activation of GLI1 in BC occurs by SMO- and cilium-independent pathways, the prediction is that pharmacological targeting of SMO with FDA-approve inhibitors will fail to prevent disease progression while targeting of GLI1 and GLI2 might be preferable. This evidence concerns the gene SMO and breast cancer.